Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Enteris BioPharma Inc.

https://enterisbiopharma.com/

Latest From Enteris BioPharma Inc.

Eight Themes That Will Shape Biopharma In Transformational 2021

A year after COVID-19 first turned the world upside down, executives across the biopharma industry consider what 2021 holds in store. The impact of the pandemic will have profound and long-lasting implications for a sector that has been at the heart of responding to the global health challenge.

Business Strategies Commercial

Scrip Asks…What Does 2021 Hold For Biopharma? Part 2: COVID-19 Shock Waves And Silver Linings

Executives expect the changes wrought by necessity in the face of a global pandemic to have lasting effects, both positive and negative, on the biopharma sector. Here they share their predictions for the coming year.

Coronavirus COVID-19 Scrip Asks

Scrip Asks…What Does 2020 Hold For Biopharma? Part 3: Policy And Regulation

The US election will intensify  the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.

Scrip Asks Pricing Debate

MSD’s Ontruzant Gets Australian Reimbursement

Merck Sharp & Dohme’s Ontruzant has become the fourth trastuzumab biosimilar to be reimbursed in Australia, while Pfizer’s Trazimera is in line to be the fifth.

Australia Biosimilars
See All

Company Information

  • Industry
  • Services
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
      • Nasal
  • Biotechnology
    • Large Molecule
  • Other Names / Subsidiaries
    • SWK Holdings Corporation
UsernamePublicRestriction

Register